Navigation Links
Gladstone scientists identify strategy to reduce toxic proteins associated with Alzheimer's disease
Date:9/22/2010

SAN FRANCISCO, CASeptember 23, 2010Scientists at the Gladstone Institute of Neurological Disease (GIND) have uncovered new approaches to reduce toxic proteins in Alzheimer's disease (AD) and other neurodegenerative diseases. The results might lead to new treatments for these diseases.

"We examined a protein called tau that has been strongly implicated in Alzheimer's disease," said Li Gan, PhD, senior author on the study. "Tau forms toxic protein aggregations in the brains of Alzheimer patients."

Tau is a common protein in the central nervous system where it helps to stabilize the cytoskeleton that supports the structure of neurons. Mutations in tau cause neurodegeneration in human brains, and tau modified by the addition of phosphate groups (p-tau) forms aggregates and damages neurons. Strategies to get rid of p-tau from neurons are sorely needed.

"We do know that levels of an enzyme called SIRT1 are reduced in AD brains and this reduction is associated with the amount of tau aggregates. We also know that SIRT1 is protective in a mouse model of neurodegeneration," said Dr. Gan. "But we didn't know how all of this fits together."

One important clue was that SIRT1 is a deacetylase, an enzyme that removes acetyl groups from proteins. Like phosphorylation, acetylation regulates many different cellular functions. "Because of this, we wanted to know if tau is acetylated," said Dr. Gan.

In this study, published in the September 23 issue of the journal Neuron, Dr. Gan's group report that, in fact, tau is acetylated. Furthermore, they found that patients at early and moderate stages of AD had elevated levels of tau acetylation.

The researchers showed that inhibiting SIRT1 increased levels of both the acetylated tau and the p-tau in neurons grown in culture dishes.

The team then wondered if inhibiting the production of acetylated tau would have an effect. Importantly, when they inhibited p300, an enzyme known to add acetyl groups to proteins, the neurons had much less acetylated tau and toxic p-tau.

The research shows that the clearance of the toxic p-tau is blocked by acetylation. "The abnormally high levels of acetylation at early stages of the disease could lead to the formation of toxic protein aggregates in AD and other neurodegenerative diseases," explained Dr. Gan.

"This study suggests that interfering with tau acetylation may be a new approach for reducing tau-related pathology," said Dr. Mucke, GIND director. "In fact, Dr. Gan and her team have already identified a small molecule compound that eliminates toxic p-tau in neurons. It might represent a new class of anti-AD drugs."


'/>"/>

Contact: Valerie Tucker
vtucker@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
Source:Eurekalert

Related biology technology :

1. ORNL scientists reveal battery behavior at the nanoscale
2. Scientists observe single ions moving through tiny carbon-nanotube channel
3. Waters Corporation and UCLA to Convene Leading Life Scientists
4. Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute
5. Scientists achieve highest-resolution MRI of a magnet
6. Univfy and Stanford Scientists Develop the First Personalized Prognostic Test to Predict Live Birth Outcomes with In Vitro Fertilization
7. Stanford scientists develop new way to grow adult stem cells in culture
8. Princeton scientists find unusual electrons that go with the flow
9. Twelve Women Scientists Announced as Winners of Elsevier Foundation TWOWS Awards
10. Scientists strive to replace silicon with graphene on nanocircuitry
11. Prestigious International Champalimaud Vision Award to US Scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Calif. , March 24, 2017   Sienna ... and aesthetics company, today announced that Richard Peterson ... effective March 24.   Peterson, who brings more ... John Smither , who is retiring at the ... in an advisory capacity. Peterson joins Sienna from Novan, ...
(Date:3/23/2017)...  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a ... solid tumor cancers, today announced that yesterday it ... last Friday, March 17, 2017. ... totaling 28,843,692 shares, comprised of 18,843,692 common shares ... Class C Warrants pre-funded at the closing at ...
(Date:3/23/2017)... Kineta, Inc., a biotechnology company focused ... immuno-oncology, today announced the discovery and characterization of ... activate interferon response factor 3 (IRF3) via RIG-I ... regression in a murine colon carcinoma mouse model.  ... tumor regression to initial drug treatment were resistant ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global ... and joint development activities. , “Dr. Floyd’s career has spanned 30 years in ...
Breaking Biology Technology:
(Date:2/21/2017)... Ore. , Feb. 22, 2017  IBM (NYSE: ... (Avamere Health Services, Infinity Rehab, Signature Hospice, Home Health, ... will apply the power of IBM cognitive computing to ... centers. By analyzing data streaming from sensors in senior ... and environmental conditions, and obtain deeper learnings into the ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
(Date:2/8/2017)... 2017 About Voice Recognition Biometrics Voice recognition ... against a stored voiceprint template. Acoustic features of ... tone are compared to distinguish between individual voices. ... most PCs already have a microphone and can ... biometrics are most likely to be deployed in ...
Breaking Biology News(10 mins):